In patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations, treatment with EGFR tyrosine kinase inhibitors (EGFR-TKIs) are now norm. Here, EGFR is linked to non-small cell lung carcinoma.